NRx Pharmaceuticals, Inc. (NRXPW)
| Market Cap | 116.55M +212.4% |
| Revenue (ttm) | 2.29M |
| Net Income | -24.54M |
| EPS | -0.97 |
| Shares Out | 36.20M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 176,260 |
| Open | 0.0033 |
| Previous Close | n/a |
| Day's Range | 0.0025 - 0.0033 |
| 52-Week Range | 0.0025 - 0.1751 |
| Beta | 2.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 15, 2026 |
About NRXPW
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for in... [Read more]
News
NRx Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 revenue rose to $1.2m, and FDA approval of preservative-free ketamine marked a shift to commercial operations. Management targets 2027 profitability while advancing drug programs and non-dilutive funding.
NRx Pharmaceuticals Quarterly report: Q3 2026
NRx Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 17, 2026.
NRx Pharmaceuticals Earnings release: Q3 2026
NRx Pharmaceuticals released its Q3 2026 earnings on November 17, 2026, summarizing the period's financial results.
NRx Pharmaceuticals reports Q3 EPS (5c), consensus (17c)
Reports Q3 revenue $1.2M, consensus $2.57M. “The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one,” said Jonathan Javitt, founder, ch...
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
FDA approved the Company's first drug, preservative-free ketamine, ahead of its GDUFA goal date; commercial launch underway with a 17-person sales force
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
WILMINGTON, Del., Nov. 12, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression...
NRx Pharmaceuticals commences selling of preservative-free ketamine
NRx Pharmaceuticals (NRXP) announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018...
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
WILMINGTON, Del., Nov. 11, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression...
NRx Pharmaceuticals Proxy statement: Proxy filing
NRx Pharmaceuticals filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
NRx Pharmaceuticals Proxy statement: Proxy filing
NRx Pharmaceuticals filed a proxy statement on November 5, 2026, providing details for shareholder voting and corporate governance matters.
NRx Pharmaceuticals Transcript: FDA announcement
FDA approved preservative-free ketamine ahead of its goal date, marking the first approved product and a move toward commercial launch. Plans center on U.S. supply, a five-million-vial launch stock, and staged expansion through 2027.
NRx Pharmaceuticals Press release: FDA announcement
NRx Pharmaceuticals issued a press release on October 30, 2026, disclosing material business information to investors.
NRx Pharmaceuticals announces FDA approval for Ketamine ANDA
NRx Pharmaceuticals (NRXP) announced that the FDA has approved the company’s Abbreviated New Drug Application, or ANDA, for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced No...
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
WILMINGTON, Del., Oct. 30, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a commercial biopharmaceutical company developing medicines that target depression...
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
Company to issue press release before market open; conference call to follow at 8:30 a.m. ET Company to issue press release before market open; conference call to follow at 8:30 a.m. ET
NRx Pharmaceuticals says NY Times retracts ‘false statements’ about NRx
NRx Pharmaceuticals (NRXP) stated: “Three days after the New York Times was notified of the false nature of its report, the paper corrected its article to state, ‘In a petition…
NRx Pharmaceuticals calls NY Times report ‘knowingly false,’ demands retraction
“The report by the New York Times alleging that NRx Pharmaceuticals (NRXP) submitted no data on the toxicity of Benzethonium Chloride is knowingly false and NRx has demanded a retraction,”…
NRx Pharmaceuticals’ Ketafree leads FDA approval race, NY Times reports
NRx Pharmaceuticals (NRXP) is advancing Ketafree, a preservative-free ketamine formulation, and is seeking FDA approval while arguing that benzethonium chloride, a preservative used in most ketamine p...
NRx Pharmaceuticals completes three process validation lots of Ketamine
NRx Pharmaceuticals (NRXP) announced completion of three process validation lots of preservative free Ketamine produced under commercial conditions in anticipation of the November 10 Generic Drug User...
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
WILMINGTON, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP, “NRx” or “the Company”), a clinical-stage biopharmaceutical company developing therapeutics based on its NM...
Psychedelic: NRx Pharmaceuticals receives FDA labeling review letter
In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a FDA request, a scientific advisor agreement and a board appointment. NRX…
NRx receives FDA review letter for Ketamine product requesting minor changes
NRx Pharmaceuticals (NRXP) announced the receipt of a “Discipline Review Letter” from the FDA requesting “minor” changes to the submitted label for NRx’s Preservative-Free Ketamine product. The letter...
NRx Pharmaceuticals Announces Receipt of FDA Labeling Review Letter for Preservative-Free Ketamine
In advance of November 10, 2026, GDUFA goal date, all requested changes were classified as “MINOR.” NRx was requested to prepare and submit labels with the proprietary name currently under review by F...
NRx Pharmaceuticals awarded initial $11.18M DARPA prime contract
NRx Defense Systems announced the award of an initial $11,177,757.27 contract issued by the Defense Advanced Research Projects Agency, DARPA, a Branch of the United States Department of War. The…
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
DARPA states that the program, if successful, will fundamentally change the Standard of Care for Treatment Resistant Depression. The Military has recognized that current treatments for depression are ...